During drug development, companies may utilize various clinical labeling-related tools that employ target labeling to facilitate drug development, while aligning the desired marketing strategy and fulfilling the clinical labeling requirements objectives. This is accomplished along with the development program design or study design and the Clinical Overview (CO) drafting. Some of the clinical labeling tools that utilize target labeling during drug development are:

  • Investigator Brochure (IB)
  • Target Labeling (TL)/Target Profile
  • Development Core Data Sheet (DCDS)
  • Development of Core Safety Information (DCSI)
  • FDA Target Product Profile (TPP)

Companies need to employ a modular approach while collecting evolving safety and efficacy information across various types of clinical labels to complement the clinical labeling requirements. This would satisfy the need to help investigators and sponsors more effectively by presenting and updating a focused and dedicated DCSI section that can conveniently be placed under these different clinical categories. Furthermore, the DCSI develops into the Company Core Safety Information (CCSI), which is included in the first Company Core Data Sheet (CCDS) and is utilized for the product's entry into the market. Drafting a thoroughly versed CO comprising the scope and critical issues in the drug's clinical development program is also required to support the documentation for the assessors.

Clinical Overview and Labeling Process

To navigate organizations through Regulatory clinical labeling requirements, Freyr offers specialized clinical labeling services.


Freyr Expertise

Creation and Review of the Investigational Brochure (IB)

Freyr has considerable expertise in the creation, authoring, and review of IBs for various clinical-stage programs of our clients. IBs are the most nascent forms of labels intended to provide the investigator or treating physician with relevant information regarding the drug/intervention. Their purpose is to provide the investigators and others involved in the trial with the information required to facilitate their understanding of the rationale for, and their compliance with, many key features of the protocol such as the dose, dose frequency/interval, methods of administration, and safety monitoring procedures. The IB contains pre-clinical and clinical information related to an investigational drug.

While working on IBs, Freyr’s clinical labeling experts present the information in a concise, simple, objective, and balanced form. The same qualities can be considered when translating documents as well. In addition to authoring IBs, Freyr also supports the annual review of IBs and works on revisions as necessary, in compliance with the standard procedures established by the clients and sponsors.  

Development of Target Labeling (TL)/ Target Profile

Development and Review of DCDS & DCSI

Freyr has proven expertise in creating high-quality DCDS which is one of the clinical labeling requirements. The DCDS is an intermediary core label that plays an important role in deriving content for first-to-file national labels (like USPI, SmPC, etc.). The DCDS/DCSI is prepared from the target label and it provides integrated safety and efficacy to an intervention or drug. The DCDS/DCSI helps investigators and sponsors more effectively by presenting and updating focused and dedicated DCDS sections that can conveniently be placed within the IB. The DCSI helps in developing CCSI, which later forms an integral part of the CCDS.

Development and Review of FDA Target Product Profile (TPP) and EU-draft SmPC (dSmPC)

Target Product Profile (TPP)/draft Summary of Product Characteristics (dSmPC) is a form of clinical label that facilitates discussions between pharmaceutical companies and Health Authorities. The TPP/dSmPC is used throughout the drug development process, from pre-investigational new drug application (pre-IND) or investigational new drug application (IND) phases of drug development through post-marketing programs to pursue new indications or other substantial changes in clinical labeling. Pharmaceutical companies specify the clinical labeling requirements and concepts that are drug development program goals in the form of TPP/dSmPC. Ideally, the TPP/dSmPC provides a statement of the overall intent of the drug development program and gives information about the drug at a particular phase of development. As a strategic Regulatory partner, Freyr has expertise in preparing TPPs for the US, and dSmPc for the EU. 


Freyr Advantages

  • Resources with in-depth Regulatory knowledge in clinical packaging and labeling.
  • Expertise in successfully handling global and regional drug labelingfor Fortune pharma clients across the globe like the USA, EUROPE, APAC, MENA, etc.
  • Global Regulatory expertise in covering Life Sciences organizations viz. pharma, biotech, and nutrition manufacturers.
  • Highly qualified medical writers possessing extensive Regulatory labeling experience.
  • In-depth and updated understanding of the global drug labeling changes from multiple Health Authorities such as the USFDA, EMA, TGA, etc.
  • Dedicated compliance team tracking the status of core and company core data sheet (CDS/CCDS) implementation in regional labels.
  • Highly experienced pharmaceutical, biotech, and nutrition labeling professionals.


To streamline end-to-end Regulatory labeling practice from creation to tracking to managing in company of any size, Freyr offers a centralized labeling life cycle management software, Freyr LABEL. Right from creating, tracking and managing company core data sheet (CCDS) deviations, CCDS updates, and developments to creating, implementing, and inspecting multi-lingual regional labels as well as custom reporting. Freyr LABEL puts companies in total control of all their Regulatory labeling compliance needs.

Would you like to decode complete information and gain a first-hand experience of Freyr LABEL?


Global HA Mandates